News & Updates

In the RECOVERY* trial, the neutralizing monoclonal antibody (mAb) sotrovimab reduces mortality in hospitalized patients with COVID-19 pneumonia with a high baseline serum SARS-CoV-2 antigen concentration. However, this was not the case in the overall population.

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.

Asthma and allergic tendency in mothers appear to elevate the risk of congenital heart defect (CHD) in their children, suggests a study, noting that nonallergic asthma also contributes to such risk.